Published: The New England Journal of Medicine
Date:
Authors: William V Tamborlane, Margarita Barrientos-Pérez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett, Ellipse Trial Investigators
Abstract:
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.
Published: American Journal of Nephrology
Date:
Authors: Meg J Jardine 1 2 , Kenneth W Mahaffey 3 , Bruce Neal 1 4 5 6 , Rajiv Agarwal 7 , George L Bakris 8 , Barry M Brenner 9 , Scott Bull 10 , Christopher P Cannon 11 , David M Charytan 12 , Dick de Zeeuw 13 , Robert Edwards 10 , Tom Greene 14 , Hiddo J L Heerspink 13 , Adeera Levin 15 , Carol Pollock 16 , David C Wheeler 17 , John Xie 10 , Hong Zhang 18 , Bernard Zinman 19 , Mehul Desai 10 , Vlado Perkovic 1 , CREDENCE study investigators
Abstract:
People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion.
Published: Current Diabetes Reports
Date:
Authors: Ramfis Nieto-Martínez 1 2 3 , Juan P González-Rivas 4 , José R Medina-Inojosa 5 , Hermes Florez 6 7
Abstract:
Eating disorders (ED) affect energy intake modifying body fat depots. Prior evidence suggests that binge eating disorder (BED) and bulimia nervosa (BN) could increase the risk for type 2 diabetes (T2D), while anorexia nervosa (AN) could reduce it.
Published: The Lancet Diabetes & Endocrinology
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Diabetes has been defined on the basis of different biomarkers, including fasting plasma glucose (FPG), 2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the effect of different diagnostic definitions on both the population prevalence of diabetes and the classification of previously undiagnosed individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health examination surveys in different regions.
Published: Am J Clin Nutr
Date:
Authors: Matthew J Delmonico 1 , Tamara B Harris, Marjolein Visser, Seok Won Park, Molly B Conroy, Pedro Velasquez-Mieyer, Robert Boudreau, Todd M Manini, Michael Nevitt, Anne B Newman, Bret H Goodpaster, Health, Aging, and Body
Abstract:
Sarcopenia is thought to be accompanied by increased muscle fat infiltration. However, no longitudinal studies have examined concomitant changes in muscle mass, strength, or fat infiltration in older adults.
Published: The Journal of Pediatrics
Date:
Authors: Robert H Lustig 1 , Michele L Mietus-Snyder, Peter Bacchetti, Ann A Lazar, Pedro A Velasquez-Mieyer, Michael L Christensen
Abstract:
To assess the use of oral glucose tolerance testing (OGTT) to predict efficacy of insulin sensitization (metformin) or suppression (octreotide) because insulin resistance and insulin hypersecretion may impact pharmacotherapeutic efficacy in obese children.